Basket/Cart is Empty
Webinars
FISH and IHC Quality Assurance: The use of Reference Slides
Presenter: Dr. Jonathan Frampton, Product Manager, Horizon Diagnostics
Date: May 21st, 2013 16:00-17:00 GMT (London time)
Clinical laboratories are routinely using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for accurate assessment of patient samples to determine the gene expression profile of oncogenes. The antibody or probe choice for FISH or IHC respectively can be a challenge for the laboratory as each choice may have a different specificity for particular genotypes.
Horizon Diagnostics has developed a portfolio of FISH and IHC Reference Slides that have been adopted into the workflow of a number of research laboratories. Data generated in these laboratories will be presented and discussed.
Register here for this Webinar
Detecting Variability in Tumor Genotyping Using NGS Platforms
Presenter: Dr. Jonathan Frampton, Product Manager, Horizon Diagnostics
Date: July 16th, 2013 15:00-16:00 GMT (London time)
Advances in next generation sequencing (Ion Torrent, Mi-Seq,…) and other multiplexing platforms (e.g. Sequenom) have provided researchers with much greater power when profiling tumor samples. However, this has presented new challenges around potential variability between samples, and consequent failure to detect biomarkers.
As multiplex assays and large tumor profiling projects become more common, standardization will be essential to enable confidence in experimental results. Using a quantitative multiplex reference standard Horizon will present data that highlights both the benefits and challenges of deploying multiplex assays for complex applications such as tumor profiling.
Register here for this Webinar
Addressing the Variability of Molecular Assays
Presenter: Dr. Jonathan Frampton, Product Manager, Horizon Diagnostics
As molecular diagnostics takes a more central role in clinical decision making, diagnostics developers and clinical laboratories have raised awareness of the critical need for quality control through standardization of technologies and methods.
Using precise gene-editing technology, Horizon Diagnostics has created a new generation of molecular reference standards. These are based on having a tightly defined allele burden and common genetic background. They are currently being used by >200 research laboratories across the world to understand the sensitivity of their molecular assays. The longer-term vision is to give clinicians the additional confidence in diagnosis and therapeutic decision making necessary to underpin personalized medicine and thereby to improve patient outcomes.
